deltatrials
Unknown PHASE2 NCT00168883

Study for Patients With Non Small Cell Lung Cancer (NSCLC)

Randomized Phase II Study to Determine the Efficacy of a Three Weekly vs. Weekly Therapy With Paclitaxel Plus Carboplatin vs. Paclitaxel Plus Vinorelbine for Patients With Non Small Cell Lung Cancer According to UICC Stage IIIB and IV

Sponsor: Bristol-Myers Squibb

Conditions Carcinoma, Non-Small-Cell Lung
Interventions Carboplatin Paclitaxel Vinorelbine
Updated 5 times since 2017 Last updated: Oct 31, 2006 Started: Oct 31, 2002 Completion: Dec 31, 2006

A PHASE2 clinical study on Carcinoma, Non-Small-Cell Lung, this trial is ongoing. The trial is conducted by Bristol-Myers Squibb and has accumulated 5 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Oct 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Charite University, Berlin, Germany
  • Pierre Fabre Pharma GmbH
Data source: Charite University, Berlin, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Berlin, Germany